LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 5 of total 5

Search options

  1. Article: An integrated approach, based on mass spectrometry, for the assessment of imidacloprid metabolism and penetration into mouse brain and fetus after oral treatment

    Passoni, Alice / Mariani, Alessandro / Comolli, Davide / Fanelli, Roberto / Davoli, Enrico / De Paola, Massimiliano / Bagnati, Renzo

    Toxicology. 2021 Oct., v. 462

    2021  

    Abstract: Imidacloprid is an insecticide belonging to neonicotinoids, a class of agonists of the nicotinic acetylcholine receptors that shows higher affinities in insects compared to mammals. However, recent evidence show that neonicotinoids can bind to the ... ...

    Abstract Imidacloprid is an insecticide belonging to neonicotinoids, a class of agonists of the nicotinic acetylcholine receptors that shows higher affinities in insects compared to mammals. However, recent evidence show that neonicotinoids can bind to the mammalian receptors, leading to detrimental responses in cultured neurons. We developed an analytical strategy which uses mass spectrometry with multiple reaction monitoring (targeted approach) and high-resolution acquisitions (untargeted approach), which were applied to quantify imidacloprid and to identify its metabolites in biological tissues after oral treatments of mice. Mouse dams were treated with doses from 0.118 mg/kg bw day up to 41 mg/kg day between gestational days 6–9. Results showed quantifiable levels of imidacloprid in plasma (from 30.48 to 5705 ng/mL) and brain (from 20.48 to 5852 ng/g) of treated mice, proving the passage through the mammalian blood-brain barrier with a high correspondence between doses and measured concentrations. Untargeted analyses allowed the identification of eight metabolites including imidacloprid-olefin, hydroxy-imidacloprid dihydroxy-imidacloprid, imidacloprid-nitrosimine, desnitro-imidacloprid, 6-chloronicotinic acid, 5-(methylsulfanyl)pyridine-2-carboxylic acid and N-imidazolidin-2-ylidenenitramide in plasma and brain. Moreover, analysis of embryonic tissues after oral treatment of mouse dams showed detectable levels of imidacloprid (816.6 ng/g after a dose of 4.1 mg/Kg bw day and 5646 ng/g after a dose of 41 mg/Kg bw day) and its metabolites, proving the permeability of the placenta barrier.Although many studies have been reported on the neurotoxicity of neonicotinoids, our study paves the way for a risk assessment in neurodevelopmental toxicity, demostrating the capability of imidacloprid and its metabolites to pass the biological barriers.
    Keywords acetylcholine ; blood-brain barrier ; brain ; fetus ; imidacloprid ; mass spectrometry ; metabolism ; metabolites ; mice ; neurotoxicity ; oral administration ; permeability ; placenta ; risk assessment ; toxicology
    Language English
    Dates of publication 2021-10
    Publishing place Elsevier B.V.
    Document type Article
    ZDB-ID 184557-3
    ISSN 1879-3185 ; 0300-483X
    ISSN (online) 1879-3185
    ISSN 0300-483X
    DOI 10.1016/j.tox.2021.152935
    Database NAL-Catalogue (AGRICOLA)

    More links

    Kategorien

  2. Article ; Online: Synergistic Pharmacological Therapy to Modulate Glial Cells in Spinal Cord Injury.

    Veneruso, Valeria / Petillo, Emilia / Pizzetti, Fabio / Orro, Alessandro / Comolli, Davide / De Paola, Massimiliano / Verrillo, Antonietta / Baggiolini, Arianna / Votano, Simona / Castiglione, Franca / Sponchioni, Mattia / Forloni, Gianluigi / Rossi, Filippo / Veglianese, Pietro

    Advanced materials (Deerfield Beach, Fla.)

    2023  Volume 36, Issue 3, Page(s) e2307747

    Abstract: Current treatments for modulating the glial-mediated inflammatory response after spinal cord injury (SCI) have limited ability to improve recovery. This is quite likely due to the lack of a selective therapeutic approach acting on microgliosis and ... ...

    Abstract Current treatments for modulating the glial-mediated inflammatory response after spinal cord injury (SCI) have limited ability to improve recovery. This is quite likely due to the lack of a selective therapeutic approach acting on microgliosis and astrocytosis, the glia components most involved after trauma, while maximizing efficacy and minimizing side effects. A new nanogel that can selectively release active compounds in microglial cells and astrocytes is developed and characterized. The degree of selectivity and subcellular distribution of the nanogel is evaluated by applying an innovative super-resolution microscopy technique, expansion microscopy. Two different administration schemes are then tested in a SCI mouse model: in an early phase, the nanogel loaded with Rolipram, an anti-inflammatory drug, achieves significant improvement in the animal's motor performance due to the increased recruitment of microglia and macrophages that are able to localize the lesion. Treatment in the late phase, however, gives opposite results, with worse motor recovery because of the widespread degeneration. These findings demonstrate that the nanovector can be selective and functional in the treatment of the glial component in different phases of SCI. They also open a new therapeutic scenario for tackling glia-mediated inflammation after neurodegenerative events in the central nervous system.
    MeSH term(s) Mice ; Animals ; Nanogels/therapeutic use ; Spinal Cord Injuries/pathology ; Neuroglia/pathology ; Microglia ; Polyethylene Glycols ; Polyethyleneimine
    Chemical Substances polyethylene glycol polyethyleneimine nanogel ; Nanogels ; Polyethylene Glycols (3WJQ0SDW1A) ; Polyethyleneimine (9002-98-6)
    Language English
    Publishing date 2023-12-02
    Publishing country Germany
    Document type Journal Article
    ZDB-ID 1474949-X
    ISSN 1521-4095 ; 0935-9648
    ISSN (online) 1521-4095
    ISSN 0935-9648
    DOI 10.1002/adma.202307747
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  3. Article ; Online: Neural cortical organoids from self-assembling human iPSC as a model to investigate neurotoxicity in brain ischemia.

    De Paola, Massimiliano / Pischiutta, Francesca / Comolli, Davide / Mariani, Alessandro / Kelk, Joe / Lisi, Ilaria / Cerovic, Milica / Fumagalli, Stefano / Forloni, Gianluigi / Zanier, Elisa R

    Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism

    2023  Volume 43, Issue 5, Page(s) 680–693

    Abstract: Brain ischemia is a common acute injury resulting from impaired blood flow to the brain. Translation of effective drug candidates from experimental models to patients has systematically failed. The use of human induced pluripotent stem cells (iPSC) ... ...

    Abstract Brain ischemia is a common acute injury resulting from impaired blood flow to the brain. Translation of effective drug candidates from experimental models to patients has systematically failed. The use of human induced pluripotent stem cells (iPSC) offers new opportunities to gain translational insights into diseases including brain ischemia. We used a human 3D self-assembling iPSC-derived model (human cortical organoids, hCO) to characterize the effects of ischemia caused by oxygen-glucose deprivation (OGD). hCO exposed to 2 h or 8 h of OGD had neuronal death and impaired neuronal network complexity, measured in whole-mounting microtubule-associated protein 2 (MAP-2) immunostaining. Neuronal vulnerability was reflected by a reduction in
    MeSH term(s) Humans ; Induced Pluripotent Stem Cells/metabolism ; Brain Ischemia/metabolism ; Oxygen/metabolism ; Cell Death ; Glucose/pharmacology ; Organoids/metabolism ; Cells, Cultured
    Chemical Substances Oxygen (S88TT14065) ; Glucose (IY9XDZ35W2)
    Language English
    Publishing date 2023-01-18
    Publishing country United States
    Document type Journal Article ; Research Support, Non-U.S. Gov't
    ZDB-ID 604628-9
    ISSN 1559-7016 ; 0271-678X
    ISSN (online) 1559-7016
    ISSN 0271-678X
    DOI 10.1177/0271678X231152023
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  4. Article ; Online: An integrated approach, based on mass spectrometry, for the assessment of imidacloprid metabolism and penetration into mouse brain and fetus after oral treatment.

    Passoni, Alice / Mariani, Alessandro / Comolli, Davide / Fanelli, Roberto / Davoli, Enrico / De Paola, Massimiliano / Bagnati, Renzo

    Toxicology

    2021  Volume 462, Page(s) 152935

    Abstract: Imidacloprid is an insecticide belonging to neonicotinoids, a class of agonists of the nicotinic acetylcholine receptors that shows higher affinities in insects compared to mammals. However, recent evidence show that neonicotinoids can bind to the ... ...

    Abstract Imidacloprid is an insecticide belonging to neonicotinoids, a class of agonists of the nicotinic acetylcholine receptors that shows higher affinities in insects compared to mammals. However, recent evidence show that neonicotinoids can bind to the mammalian receptors, leading to detrimental responses in cultured neurons. We developed an analytical strategy which uses mass spectrometry with multiple reaction monitoring (targeted approach) and high-resolution acquisitions (untargeted approach), which were applied to quantify imidacloprid and to identify its metabolites in biological tissues after oral treatments of mice. Mouse dams were treated with doses from 0.118 mg/kg bw day up to 41 mg/kg day between gestational days 6-9. Results showed quantifiable levels of imidacloprid in plasma (from 30.48 to 5705 ng/mL) and brain (from 20.48 to 5852 ng/g) of treated mice, proving the passage through the mammalian blood-brain barrier with a high correspondence between doses and measured concentrations. Untargeted analyses allowed the identification of eight metabolites including imidacloprid-olefin, hydroxy-imidacloprid dihydroxy-imidacloprid, imidacloprid-nitrosimine, desnitro-imidacloprid, 6-chloronicotinic acid, 5-(methylsulfanyl)pyridine-2-carboxylic acid and N-imidazolidin-2-ylidenenitramide in plasma and brain. Moreover, analysis of embryonic tissues after oral treatment of mouse dams showed detectable levels of imidacloprid (816.6 ng/g after a dose of 4.1 mg/Kg bw day and 5646 ng/g after a dose of 41 mg/Kg bw day) and its metabolites, proving the permeability of the placenta barrier. Although many studies have been reported on the neurotoxicity of neonicotinoids, our study paves the way for a risk assessment in neurodevelopmental toxicity, demostrating the capability of imidacloprid and its metabolites to pass the biological barriers.
    MeSH term(s) Administration, Oral ; Animals ; Blood-Brain Barrier/metabolism ; Brain/metabolism ; Dose-Response Relationship, Drug ; Female ; Fetus/metabolism ; Insecticides/analysis ; Insecticides/pharmacokinetics ; Male ; Mass Spectrometry/methods ; Mice ; Neonicotinoids/administration & dosage ; Neonicotinoids/analysis ; Neonicotinoids/pharmacokinetics ; Nitro Compounds/administration & dosage ; Nitro Compounds/analysis ; Nitro Compounds/pharmacokinetics ; Placenta/metabolism ; Pregnancy ; Tissue Distribution
    Chemical Substances Insecticides ; Neonicotinoids ; Nitro Compounds ; imidacloprid (3BN7M937V8)
    Language English
    Publishing date 2021-09-09
    Publishing country Ireland
    Document type Journal Article ; Research Support, Non-U.S. Gov't ; Validation Study
    ZDB-ID 184557-3
    ISSN 1879-3185 ; 0300-483X
    ISSN (online) 1879-3185
    ISSN 0300-483X
    DOI 10.1016/j.tox.2021.152935
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  5. Article ; Online: Effect of Lactoferrin on Clinical Outcomes of Hospitalized Patients with COVID-19: The LAC Randomized Clinical Trial.

    Matino, Erica / Tavella, Elena / Rizzi, Manuela / Avanzi, Gian Carlo / Azzolina, Danila / Battaglia, Antonio / Becco, Paolo / Bellan, Mattia / Bertinieri, Giovanni / Bertoletti, Massimo / Casciaro, Giuseppe Francesco / Castello, Luigi Mario / Colageo, Umberto / Colangelo, Donato / Comolli, Davide / Costanzo, Martina / Croce, Alessandro / D'Onghia, Davide / Della Corte, Francesco /
    De Mitri, Luigi / Dodaro, Valentina / Givone, Filippo / Gravina, Alessia / Grillenzoni, Luca / Gusmaroli, Graziano / Landi, Raffaella / Lingua, Anna / Manzoni, Roberto / Marinoni, Vito / Masturzo, Bianca / Minisini, Rosalba / Morello, Marina / Nelva, Anna / Ortone, Elena / Paolella, Rita / Patti, Giuseppe / Pedrinelli, Anita / Pirisi, Mario / Ravizzi, Lidia / Rizzi, Eleonora / Sola, Daniele / Sola, Mariolina / Tonello, Nadir / Tonello, Stelvio / Topazzo, Gigliola / Tua, Aldo / Valenti, Piera / Vaschetto, Rosanna / Vassia, Veronica / Zecca, Erika / Zublena, Nicoletta / Manzoni, Paolo / Sainaghi, Pier Paolo

    Nutrients

    2023  Volume 15, Issue 5

    Abstract: As lactoferrin is a nutritional supplement with proven antiviral and immunomodulatory abilities, it may be used to improve the clinical course of COVID-19. The clinical efficacy and safety of bovine lactoferrin were evaluated in the LAC randomized double- ...

    Abstract As lactoferrin is a nutritional supplement with proven antiviral and immunomodulatory abilities, it may be used to improve the clinical course of COVID-19. The clinical efficacy and safety of bovine lactoferrin were evaluated in the LAC randomized double-blind placebo-controlled trial. A total of 218 hospitalized adult patients with moderate-to-severe COVID-19 were randomized to receive 800 mg/die oral bovine lactoferrin (n = 113) or placebo (n = 105), both given in combination with standard COVID-19 therapy. No differences in lactoferrin vs. placebo were observed in the primary outcomes: the proportion of death or intensive care unit admission (risk ratio of 1.06 (95% CI 0.63-1.79)) or proportion of discharge or National Early Warning Score 2 (NEWS2) ≤ 2 within 14 days from enrollment (RR of 0.85 (95% CI 0.70-1.04)). Lactoferrin showed an excellent safety and tolerability profile. Even though bovine lactoferrin is safe and tolerable, our results do not support its use in hospitalized patients with moderate-to-severe COVID-19.
    MeSH term(s) Adult ; Humans ; COVID-19 ; Lactoferrin ; Double-Blind Method ; Antiviral Agents/therapeutic use ; Treatment Outcome
    Chemical Substances Lactoferrin (EC 3.4.21.-) ; Antiviral Agents
    Language English
    Publishing date 2023-03-04
    Publishing country Switzerland
    Document type Randomized Controlled Trial ; Journal Article
    ZDB-ID 2518386-2
    ISSN 2072-6643 ; 2072-6643
    ISSN (online) 2072-6643
    ISSN 2072-6643
    DOI 10.3390/nu15051285
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

To top